Benefits
Cortisol reduction (women-specific application)
RiaGev-FEM clinically proven to naturally reduce cortisol levels in shorter time than other cortisol-lowering ingredients, without side effects. Cortisol is responsible for a majority of menopausal symptoms — cortisol-related changes often begin well before a woman experiences her first menopausal symptom. Addresses the underlying driver across the entire menopausal spectrum.
NAD+ increase (10-11% over baseline)
In a clinical pilot, 1,540 mg twice daily for 5 days significantly increased blood NAD+ by 11% over baseline and 10.4% vs placebo. NAD+ is critical for cellular energy production and declines with age. ATP levels drop markedly after age 60, so boosting NAD+ supports cellular function across aging.
Glutathione (master antioxidant) elevation
The same trial documented significantly higher serum glutathione vs placebo. Glutathione is the body's master antioxidant, protecting against oxidative damage at the cellular level. Elevated glutathione supports cellular protection across aging and stress contexts, particularly relevant for women experiencing menopausal oxidative stress increases.
Blood glucose reduction (insulin sensitivity)
Significant reductions in overall blood glucose without significant changes in insulin secretion — suggesting improved insulin sensitivity and glucose tolerance. Menopausal women face increasing metabolic risk including insulin resistance. RiaGev addresses this metabolic component alongside cortisol and antioxidant effects.
Energy, fatigue, and mental concentration improvements
The RiaGev group consistently scored greater improvements than placebo on physical fatigue, mental concentration, motivation, and physical activities (Checklist Individual Strength questionnaire). These multi-parameter well-being improvements address common menopausal symptoms beyond hot flashes, including brain fog, fatigue, and motivation.
Sleep quality (unpublished researcher notes)
Researchers' unpublished logs noted sleep improvements in the RiaGev group. Sleep disruption is a major menopausal complaint, and cortisol dysregulation drives nighttime awakening. Addressing cortisol naturally supports sleep improvement as a downstream benefit alongside the broader applications.
Multi-stage menopausal spectrum support
Works to alleviate cortisol-dependent symptoms across the entire menopausal spectrum: perimenopause, premenopause, menopause, and postmenopause. Women can feel the difference at any stage. Distinguished from phytoestrogen-based ingredients that primarily target later-stage menopausal symptoms — RiaGev-FEM addresses the broader cortisol dysregulation timeline.
No side effects (vs other NAD precursors)
RiaGev-FEM enables women's health products to be more effective with no known side effects. Distinguishes from other NAD precursors (like niacin/nicotinic acid) that can cause flushing. The well-tolerated profile supports long-term daily use across the menopausal spectrum.
Mechanism of action
NAD salvage pathway direct activation
RiaGev enters the NAD salvage pathway directly via the combination of D-ribose (provides the ribose moiety) and nicotinamide (the niacin component). Distinguished from NMN, NR, and other NAD precursors by acting downstream — closer to NAD+ synthesis itself. Direct salvage pathway entry supports efficient NAD+ production.
HPA axis cortisol modulation
RiaGev-FEM reduces cortisol levels — modulating the hypothalamic-pituitary-adrenal (HPA) axis. The cortisol-lowering mechanism appears more efficient than typical adaptogens or chronic stress management ingredients. The specific mechanism by which D-ribose + nicotinamide modulates cortisol remains under investigation but the clinical effect is documented.
Cellular bioenergetics
Bioenergy Ribose enables ATP production by providing the ribose precursor for ATP synthesis. ATP levels drop with age, most dramatically after age 60 — supporting bioenergetics addresses the underlying cellular fatigue that drives many menopausal symptoms. Combined with NAD+ effects, supports comprehensive cellular energy.
Glutathione synthesis support
NAD+ is required for glutathione synthesis via the NADPH-dependent glutathione reductase enzyme. Elevated NAD+ supports glutathione production and recycling. Mechanism explains the dual NAD+ and glutathione elevation documented in clinical trials — both occurring simultaneously via the connected pathways.
Insulin sensitivity enhancement
NAD+ is critical for cellular insulin signaling and glucose disposal. Elevated NAD+ supports improved insulin sensitivity — explaining the blood glucose reductions without significant insulin changes. The mechanism is particularly relevant for menopausal women facing increased metabolic risk.
Clinical trials
Single-centre randomised double-blind comparator-controlled cross-over study evaluating RiaGev safety and efficacy in healthy men and women ages 36-65. 1,540 mg dosed twice daily for 5-7 days. Investigated circulating NAD+ and NADP+ levels, ATP/ADP ratios, glutathione induction, and cortisol effects. Published trial foundation for RiaGev-FEM women-specific applications.
Healthy middle-aged men and women aged 36-65. Cross-over design with 5-7 day intervention periods.
10.4-11% NAD+ increase in serum over baseline and placebo. Significantly higher glutathione levels in serum. Significantly reduced cortisol (primary adrenal stress hormone). Significant blood glucose reductions without insulin changes (improved insulin sensitivity). Greater improvements in physical fatigue, mental concentration, motivation, physical activities (CIS questionnaire). Sleep improvements noted in unpublished logs.
Women-specific clinical studies on RiaGev-FEM evaluating cortisol reduction in women across the menopausal spectrum. Foundation for RiaGev-FEM commercial positioning for women's health. Studies demonstrate more bioavailable and faster cortisol reduction than other ingredients without side effects.
Women across the menopausal spectrum (perimenopause, premenopause, menopause, postmenopause).
RiaGev-FEM clinically proven to naturally reduce cortisol levels in a shorter amount of time than other cortisol-lowering ingredients, without side effects. Effective at alleviating cortisol-dependent symptoms across the entire menopausal spectrum. Supports broader women's health products formulation as standalone or combined with other beneficial botanicals and bioactives.
Preclinical data demonstrating RiaGev safely strengthens the NAD salvage pathway and increases NAD across all tissues. Foundation for the broader healthy aging applications. Distinguishes RiaGev's mechanism from other NAD precursors (NMN, NR) by entering the salvage pathway at a different step.
Not applicable — preclinical mechanistic research base.
RiaGev increases NAD across all tissues via direct NAD salvage pathway entry. Distinguished from NMN/NR precursors by combining ribose and nicotinamide components together — mimicking the natural NAD+ structure (ribose + nicotinamide). Safety profile supports long-term applications across healthy aging and women's health categories.